Related Experiment Video

Updated: May 22, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Diabetic cardiovascular disease--AMP-activated protein kinase (AMPK) as a therapeutic target

Marie-Ann Ewart1, Simon Kennedy

  • 1Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, G12 8QQ, UK.

Cardiovascular & Hematological Agents in Medicinal Chemistry
|May 29, 2012
PubMed

Insights

AMPK activation shows promise for treating cardiovascular disease in diabetes by improving cell function and offering protection against injury. Further research into AMPK activators could lead to new therapies for diabetic cardiovascular complications.

Area of Science:

  • Biochemistry
  • Cardiology
  • Endocrinology

Background:

  • Cardiovascular complications are the primary cause of death in diabetic patients.
  • Normoglycaemia alone has limited impact on cardiovascular outcomes in diabetes.
  • Novel therapeutic strategies are essential for reducing cardiovascular disease incidence and improving outcomes in diabetic individuals.

Purpose of the Study:

  • To explore AMP-activated protein kinase (AMPK) as a therapeutic target for diabetic vascular disease.
  • To detail the downstream targets of AMPK activation within the cardiovascular system.
  • To review existing and novel AMPK activators for potential therapeutic applications.

Main Methods:

  • Review of existing literature on AMPK activation and its cardiovascular effects.
  • Analysis of studies investigating AMPK's role in endothelial and smooth muscle cell function.
  • Examination of research on AMPK's impact on lipid profiles, cardiomyocyte growth, and ischemia-reperfusion injury.

Main Results:

  • AMPK activation improves endothelial and smooth muscle cell function.
  • AMPK therapy offers benefits including improved lipid profiles and protection against cardiac ischemia-reperfusion injury.
  • AMPK activation reduces hypertrophic cardiomyocyte growth.

Conclusions:

  • AMPK is a promising therapeutic target for cardiovascular disease in diabetes.
  • Understanding AMPK's downstream targets is crucial for developing effective treatments.
  • Further investigation of novel AMPK activators holds significant potential for managing diabetic cardiovascular complications.

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...